Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of Matriptase

A transmembrane region, chronic technology, applied in the evaluation of curative effect and prognosis, treatment, chronic lymphocytic leukemia disease diagnosis, can solve the problem of unclear biological function

Inactive Publication Date: 2012-09-12
SUZHOU UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Recent studies have found that Matriptase is slightly expressed in peripheral blood monocytes and macrophages, but its biological function in blood is still unclear

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Matriptase
  • Application of Matriptase
  • Application of Matriptase

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0021] The present invention will be described in detail below with reference to the accompanying drawings and in combination with embodiments.

[0022] The application of Matriptase, the Matriptase is applied in the diagnosis and treatment of chronic lymphocytic leukemia. see figure 1 As shown, the Matriptase includes a short intracellular segment, a transmembrane region, a SEA region (sea urchin sperm protein, enteropeptidase, agrin domain), two CUB regions (Cls / Clr, urchin embryonic growth factor and bone morphogenetic protein-1), four low-density lipoprotein receptor (LDLRA) domains, and a C-terminal trypsin-like protease region, the Matriptase is used in the diagnosis and treatment of chronic lymphocytic leukemia.

[0023] Further, the Matriptase is used as a diagnostic index for chronic lymphocytic leukemia.

[0024] Further, the Matriptase serves as a new target for the treatment of chronic lymphocytic leukemia.

[0025] The specific implementation process:

[0026]...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Matriptase. The Matriptase comprises a short intracellular segment, a transmembrane region, an SEA (sea urchin sperm protein, enteropeptidase, agrin domain) region, two CUB (Cls / Clr, urchin embryonic growth factor and bone morphogenetic protein-1) regions, four low density lipoprotein acceptor domains and a C-terminal trypsin-like protease region. The Matriptase is applied to diagnosis and treatment of chronic lymphocyte leukemia. By an experiment, bone marrows and peripheral blood specimens of normal people and leukemia sufferers are collected, and the detection result shows as follows: Matriptase mRNA and protein are highly expressed in the chronic lymphocyte leukemia sufferers, the expression level of Matriptase of the surface of lymphocyte can serve as a molecular marker for diagnosis of chronic lymphocyte leukemia, and the Matriptase can serve as a novel target for diagnosis and treatment of chronic lymphocyte leukemia.

Description

[0001] technical field [0002] The invention relates to the field of biotechnology, specifically, the role of Matriptase in the diagnosis, treatment, curative effect evaluation and prognosis of chronic lymphocytic leukemia. Background technique [0003] Leukemia is a malignant blood tumor, and its incidence rate is increasing year by year. Among them, chronic lymphocytic leukemia is a blood tumor in which B-lineage lymphocytes resist apoptosis and clonally accumulate in lymphoid tissue, bone marrow and peripheral blood, eventually leading to normal hematopoietic failure. . The incidence of chronic lymphocytic leukemia in Western countries is about 30% of all leukemias, and the incidence in China and Asian countries is less than 10%, and it has been increasing in recent years. Chronic lymphocytic leukemia cells are characterized by strong viability and inhibited apoptosis, and its pathogenesis is still unclear. Therefore, it is of great significance and clinical value to ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/574
Inventor 吴庆宇董宁征高丽娟刘萌
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com